Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents — GenV  

Obesity Clinical Trial

Official title: Generation Victoria Cohort 2020s. A Statewide Longitudinal Cohort of Victorian Children and Their Parents

Status Recruiting

Clinical Trial Summary

Generation Victoria (GenV) is a longitudinal, population-based study of Victorian children and their parents that will bring together data on a wide range of conditions, exposures and outcomes. GenV blends study-collected, study-enhanced and linked data. It will be multi-purpose, supporting observational, interventional, health services and policy research within the same cohort. It is designed to address physical, mental and social issues experienced during childhood, as well as the antecedents of a wide range of diseases of ageing. It seeks to generate translatable evidence (prediction, prevention, treatments, services) to improve future wellbeing and reduce the future disease burden of children and adults.

The GenV Cohort 2020s is open to all babies born over a two-year period, and their parents, residing in the state of Victoria Australia. The GenV Cohort 2020s is preceded by an Advance Cohort of babies born between 5 Dec 2020 and 3 October 2021, and their parents. This comprises all families recruited at GenV's Vanguard hospital (Joan Kirner Women's and Children's) and at birthing hospitals throughout Victoria as GenV scaled up to commence recruiting for the GenV Cohort 2020s. The Advance Cohort have ongoing and full participation in GenV for their lifetime unless they withdraw but may have less complete data and biosamples.

Clinical Trial Description

GenV aims to create large, parallel whole-of-state birth and parent cohorts for discovery and interventional research. GenV's key features ('building blocks') are:

• Consent - Consent soon after birth, targeting every family having a baby in Victoria across in a 2-year period;

• Biosamples - Curation of universal biosamples already collected and stored, and new biosamples collected directly by GenV;

• Linked data - Ongoing access to extensive administrative, service, clinical and geospatial datasets, including prospectively-collected preconception and prenatal datasets;

• GenV-collected data - Information collected from participants via GenV and/or in partnership with services, and face-to-face direct assessment once at school;

• Integrated studies - Collaborative research involving GenV participants in concurrent research studies embedded within or alongside GenV, with ethically supported agreements and data sharing arrangements (for example, trials, other interventional studies, depth sub-cohorts, registry-type research);

• Platform as a service - Safe and efficient platforms and processes that support diverse users to access and/or analyse the resources and datasets generated by GenV to maximise their benefit to human health, and support GenV to meet its commitment to transparency and Open Science.

GenV focuses on 10 big issues: COVID, healthy pregnancy, healthy newborns, equity, climate & environment, mental health, healthy development, allergy & immunity, infection, and obesity & diabetes, with a cross cutting commitment of population genomics. These focus areas drive current planning for data collection but are not intended to be exhaustive and may change over the life of the project.

GenV is working with partners at all birthing hospitals across Victoria (ie 58 hospital sites). Recruitment visits are completed by trained study staff with clinical and/or research backgrounds at the participant's hospital or via virtual and/or self-guided recruitment after discharge (including initial GenV-collected data and biosamples). Participant-provided data will be collected digitally (e.g. via website or smart phone app) about four times per year from age 3 months to 1 year, then 6-12 monthly until 5 years, and is expected to take 3-20 minutes per session. A face-to-face visit is planned for when the index child is around 6 years of age, completed by trained study staff with clinical and/or research backgrounds. The project duration is expected to be at least 10 years and potentially lifelong for its participants, dependant on study funding and willingness to continue.

Based on Victoria's annual birth rate and estimated post-pandemic fall, GenV estimates that the sampling frame for the main Cohort 2020s will comprise 150,000 children, 150,000 'primary' biological parents, and 130,000 (i.e. for 90 percent of children) second parents. GenV is preparing for a recruitment sample of up to 90 percent of children while recognising that uptake as low as 13 percent would still be valuable (i.e. sufficient to detect odds ratios of around 1.5 for an outcome with 1.5 percent prevalence and an exposure with 20 percent prevalence). At submission of this registration, our target sample size is 200,000 participants (80,000 children, 80,000 primary parents and 40,000 second parents). This would represent a 53 percent uptake from our potential denominator of all 150,000 babies born over a 24-month period and their primary parent, and half that for their secondary parent. ;

Related Conditions & MeSH terms

• Allergy and Immunology
• Child Development
• Child Health
• Child Wellbeing
• Cognition
• Communicable Diseases
• Congenital Abnormalities
• Diet
• Disability
• Environmental Exposure
• Genetics
• Health Equity
• Healthy Aging
• Infant Health
• Infections
• Inflammation
• Injuries
• Intergenerational Relations
• Learning
• Mental Health
• Noncommunicable Diseases
• Obesity
• Physical Fitness
• Quality of Life
• Reproductive Health
• Social Determinants of Health

• NCT number: NCT05394363
• Study type: Observational
• Source: Murdoch Childrens Research Institute
• Contact: GenV Cohort Coordinator
• Phone: +61 1800 436 888
• Email: genv@mcri.edu.au
• Status: Recruiting
• Start date: October 4, 2021
• Completion date: October 2033